Gensight Biologics SA Stock
Your prediction
Gensight Biologics SA Stock
There is no change in the price for Gensight Biologics SA today.
Our community identified positive and negative aspects for Gensight Biologics SA stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Gensight Biologics SA stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Gensight Biologics SA in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
B****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Gensight Biologics SA vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Gensight Biologics SA | 0.000% | -12.613% | 5.476% | -65.730% | -15.079% | -97.373% | -98.871% |
| India Globalization Capital | 0.000% | 2.459% | -8.759% | -18.301% | 5.042% | -16.639% | -79.780% |
| Protara Therapeutics Inc. | -0.900% | 5.727% | -4.000% | -10.280% | 7.623% | 75.182% | -71.598% |
| BioInvent International AB | 0.180% | 1.457% | 11.400% | 3.532% | 3.724% | -9.724% | -46.545% |
Comments
News
GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
